Head-to-head · Cost-Efficiency Index
Kin Meds vs Roen Rx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Kin Meds
Shoppers modeling the real monthly cost before they commit.
Visit Kin MedsRoen Rx
Cost-first shoppers who want insured shoppers chasing a low brand-name copay via RoenRx's insurance coordination, with a compounded fallback.
Visit Roen RxThe verdict
Kin Meds takes it, leading the Cost-Efficiency Index 47 to 46. Kin Meds is a GLP-1 telehealth provider whose own website could not be accessed for live verification due to active bot-protection/CAPTCHA (confirmed via direct fetch, a text-rendering proxy, and live browser automation). Roen Rx still earns a C — Cost-first shoppers who want insured shoppers chasing a low brand-name copay via RoenRx's insurance coordination, with a compounded fallback.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Kin Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Kin Meds | Roen Rx |
|---|---|---|
| Cost-Efficiency Index | 47/100 | 46/100 |
| Semaglutide / mo | Not disclosed | $151/mo (starting dose, 3-month plan, plus a separate fee, compounded) |
| Tirzepatide / mo | Not disclosed | $216/mo (starting dose, plus a separate fee, compounded) |
| Semaglutide / yr (modeled) | — | $1,812 |
| Tirzepatide / yr (modeled) | — | $2,592 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Yes |
| Rank here | #447 | #454 |
Kin Meds
47/100Where the value is
- Appears to have an established web/social presence per search results
The tradeoffs
- Site is unreachable for independent verification behind active bot/CAPTCHA protection
- No pricing, medical director, or pharmacy partner could be confirmed directly from the company
Regulatory note: the FDA issued a warning letter to Kin Meds in February 2026. We still list and link to Kin Meds; you should know the letter is on the public record before you decide.
Roen Rx
46/100Where the value is
- Insurance coordination path can bring brand-name GLP-1s down to as low as $25/mo for covered patients
- Both compounded and brand-name (Ozempic, Wegovy, Zepbound, Mounjaro) options on one platform
- Explicitly serves all 50 states and DC
The tradeoffs
- The advertised LegitScript badge on the homepage is literally commented out in the page's HTML source and never renders on the live site — despite being present in source, it is not a real, visible certification a visitor sees
- Medication cost and membership fee are billed separately; the membership's regular (non-promotional) monthly price is never disclosed anywhere checked, only the '$39 first month' discount
Regulatory note: the FDA issued a warning letter to Roen Health, Inc. dba RoenRx in June 2026. We still list and link to Roen Rx; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.